Compassionate use of everolimus in a patient with a neuroendocrine tumor: A case report and discussion of the literature

Research output: Contribution to journalArticle

Abstract

Neuroendocrine tumors (NETs) represent a relatively rare form of neoplasias for which, in advanced unresectable stages, palliative treatment options remain limited largely to the use of somatostatin analogues or chemotherapy. Several newer targeted therapeutic options, alone or in combination with somatostatin analogues, are currently undergoing clinical evaluation for the treatment of NETs. This article reports the compassionate use of everolimus in combination with long-acting octreotide, in a 58-year old Italian female patient with a well-differentiated neuroendocrine gastric tumor who, since October 2004, has failed multiple previous therapies. Starting in October 2008, the patient has received intramuscular octreotide LAR 30 mg every 28 days plus everolimus 10 mg/day. The patient has reported benefits of symptoms (reduction of pain severity), objective response [improvement of liver function (reductions in LDH, ALP and total bilirubin) and chromogranin A], and radiological response (reduction in target lesions on CT). The patient has experienced an improved quality of life, increased life expectancy, and remains on this well-tolerated treatment regimen.

Original languageEnglish
Pages (from-to)403-406
Number of pages4
JournalOncology Research
Volume19
Issue number8-9
DOIs
Publication statusPublished - 2011

Fingerprint

Compassionate Use Trials
Neuroendocrine Tumors
Octreotide
Somatostatin
Chromogranin A
Therapeutics
Life Expectancy
Palliative Care
Bilirubin
Stomach
Quality of Life
Drug Therapy
Pain
Everolimus
Liver
Neoplasms

Keywords

  • Compassionate use
  • Everolimus
  • Neuroendocrine tumor
  • Octreotide
  • Targeted therapies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{5923dc8eb4704667885b11d284efa398,
title = "Compassionate use of everolimus in a patient with a neuroendocrine tumor: A case report and discussion of the literature",
abstract = "Neuroendocrine tumors (NETs) represent a relatively rare form of neoplasias for which, in advanced unresectable stages, palliative treatment options remain limited largely to the use of somatostatin analogues or chemotherapy. Several newer targeted therapeutic options, alone or in combination with somatostatin analogues, are currently undergoing clinical evaluation for the treatment of NETs. This article reports the compassionate use of everolimus in combination with long-acting octreotide, in a 58-year old Italian female patient with a well-differentiated neuroendocrine gastric tumor who, since October 2004, has failed multiple previous therapies. Starting in October 2008, the patient has received intramuscular octreotide LAR 30 mg every 28 days plus everolimus 10 mg/day. The patient has reported benefits of symptoms (reduction of pain severity), objective response [improvement of liver function (reductions in LDH, ALP and total bilirubin) and chromogranin A], and radiological response (reduction in target lesions on CT). The patient has experienced an improved quality of life, increased life expectancy, and remains on this well-tolerated treatment regimen.",
keywords = "Compassionate use, Everolimus, Neuroendocrine tumor, Octreotide, Targeted therapies",
author = "Sara Pusceddu and Massimo Milione and Giuseppe Procopio",
year = "2011",
doi = "10.3727/096504011X13123323849799",
language = "English",
volume = "19",
pages = "403--406",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "8-9",

}

TY - JOUR

T1 - Compassionate use of everolimus in a patient with a neuroendocrine tumor

T2 - A case report and discussion of the literature

AU - Pusceddu, Sara

AU - Milione, Massimo

AU - Procopio, Giuseppe

PY - 2011

Y1 - 2011

N2 - Neuroendocrine tumors (NETs) represent a relatively rare form of neoplasias for which, in advanced unresectable stages, palliative treatment options remain limited largely to the use of somatostatin analogues or chemotherapy. Several newer targeted therapeutic options, alone or in combination with somatostatin analogues, are currently undergoing clinical evaluation for the treatment of NETs. This article reports the compassionate use of everolimus in combination with long-acting octreotide, in a 58-year old Italian female patient with a well-differentiated neuroendocrine gastric tumor who, since October 2004, has failed multiple previous therapies. Starting in October 2008, the patient has received intramuscular octreotide LAR 30 mg every 28 days plus everolimus 10 mg/day. The patient has reported benefits of symptoms (reduction of pain severity), objective response [improvement of liver function (reductions in LDH, ALP and total bilirubin) and chromogranin A], and radiological response (reduction in target lesions on CT). The patient has experienced an improved quality of life, increased life expectancy, and remains on this well-tolerated treatment regimen.

AB - Neuroendocrine tumors (NETs) represent a relatively rare form of neoplasias for which, in advanced unresectable stages, palliative treatment options remain limited largely to the use of somatostatin analogues or chemotherapy. Several newer targeted therapeutic options, alone or in combination with somatostatin analogues, are currently undergoing clinical evaluation for the treatment of NETs. This article reports the compassionate use of everolimus in combination with long-acting octreotide, in a 58-year old Italian female patient with a well-differentiated neuroendocrine gastric tumor who, since October 2004, has failed multiple previous therapies. Starting in October 2008, the patient has received intramuscular octreotide LAR 30 mg every 28 days plus everolimus 10 mg/day. The patient has reported benefits of symptoms (reduction of pain severity), objective response [improvement of liver function (reductions in LDH, ALP and total bilirubin) and chromogranin A], and radiological response (reduction in target lesions on CT). The patient has experienced an improved quality of life, increased life expectancy, and remains on this well-tolerated treatment regimen.

KW - Compassionate use

KW - Everolimus

KW - Neuroendocrine tumor

KW - Octreotide

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=84255187612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84255187612&partnerID=8YFLogxK

U2 - 10.3727/096504011X13123323849799

DO - 10.3727/096504011X13123323849799

M3 - Article

C2 - 22329200

AN - SCOPUS:84255187612

VL - 19

SP - 403

EP - 406

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 8-9

ER -